Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02475733 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT02475733 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 83 participants.
The verdict
NCT02475733, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
This study will assess the safety , efficacy and pharmacokinetics of ceftazidime avibactam and metronidazole versus meropenem in paediatric population (from 3 months to less than 18 years of age )with complicated intra-abdominal infections (cIAIs)
Interventions
- DRUG Metronidazole
- DRUG Meropenem
- DRUG Ceftazidime -avibactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2015-08-01 |
| Est. Completion | 2017-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02475733
The ClinicalTrials.gov registry entry for NCT02475733 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metronidazole is the first listed.
NCT02475733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02475733 about?
NCT02475733 is a clinical study titled "Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).". This study will assess the safety , efficacy and pharmacokinetics of ceftazidime avibactam and metronidazole versus meropenem in paediatric population (from 3 months to less than 18 years of age )with complicated intra-abdominal infections (cIAIs)
What is the current status of trial NCT02475733?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2015-08-01. Estimated completion is 2017-06-01.
What interventions are being tested in trial NCT02475733?
The interventions under investigation include: Metronidazole (DRUG), Meropenem (DRUG), Ceftazidime -avibactam (DRUG).
Who is sponsoring clinical trial NCT02475733?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.